<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04478643</url>
  </required_header>
  <id_info>
    <org_study_id>PERIOPRO np.: 3965</org_study_id>
    <nct_id>NCT04478643</nct_id>
  </id_info>
  <brief_title>Lactobacillus Reuteri in the Supportive Therapy of Periodontitis</brief_title>
  <acronym>PERIOPRO</acronym>
  <official_title>Clinical and Microbiological Efficacy of Lactobacillus Reuteri in the Supportive Therapy of Periodontitis: a 6 Months Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Literature shows the potential effectiveness of L. reuteri as an adjunct to non-surgical&#xD;
      periodontal therapy in initial treatment of periodontitis, but also underlines the limits of&#xD;
      the conclusions, and the heterogeneity and limited sample size of the available studies.&#xD;
      Therefore, there is a need for longer-term, randomized, controlled studies. Moreover, only&#xD;
      one study addresses the use of this probiotic during the supportive therapy, in particular in&#xD;
      patients with severe forms of periodontitis, and only few patients were included.&#xD;
&#xD;
      Patients meeting the criteria of periodontitis stage III and IV, grade C are considered to be&#xD;
      affected by severe and advanced forms of periodontitis with a rapid rate of progression. This&#xD;
      group of patients could particularly benefit from supplements for the maintenance of&#xD;
      periodontal health.&#xD;
&#xD;
      The hypothesis of the present randomized controlled trial is that the adjunctive use of&#xD;
      probiotic treatment can bring clinical and microbiological advantages during the supportive&#xD;
      therapy of periodontal disease, and reduce the number of residual pockets.&#xD;
&#xD;
      To test this hypothesis, the patients, upon initial evaluation, will be divided in 2 study&#xD;
      groups and, after a session of professional oral hygiene, will be prescribed one of the&#xD;
      therapies below:&#xD;
&#xD;
        -  PLACEBO: The patients of the control group will receive control lozenges without live&#xD;
           bacteria;&#xD;
&#xD;
        -  TEST: The patients of the probiotic group will receive probiotic lozenges containing&#xD;
           Lactobacillus reuteri DSM 17938 and Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2&#xD;
           × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB).&#xD;
&#xD;
      The probiotic and control lozenges will be identical in taste, texture and appearance. The&#xD;
      lozenges will be given to all patients to consume at home. The patients will be instructed to&#xD;
      dissolve them on their tongue twice a day, preferably after brushing, for 3 weeks.&#xD;
&#xD;
      Periodontal and microbiological parameters will be evaluated at 3 and 6 months after the&#xD;
      initial therapy, and compared between the two groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Probiotics are defined as 'live microorganisms which, when administered in adequate amounts,&#xD;
      confer a health benefit on the host'. The influence of probiotics on pathogens flora can&#xD;
      derive from three principal modes of action: innate and acquired host defense modulation,&#xD;
      production of antibacterial substances and competitive exclusion mechanism. In particular,&#xD;
      Lactobacillus reuteri has been studied for its antibacterial and anti-inflammatory&#xD;
      properties.&#xD;
&#xD;
      It is a heterofermentative bacterium and the distinct strains have different characteristics.&#xD;
      In particular it acts as an antibiotic, induces oxidative stress on pathogens, is resistant&#xD;
      to proteolytic and lipolytic and present anti-inflammatory properties.&#xD;
&#xD;
      TRIAL DESIGN Parallel-arm, mono-center, statistician operator and examiner blinded RCT. The&#xD;
      trial will have 6 months of duration.&#xD;
&#xD;
      STUDY POPULATION Forty-four (44) adults, aged 18-75 years, meeting the criteria of&#xD;
      periodontitis stage III and IV, grade C, will be entered into study. It is expected that&#xD;
      forty (40) subjects will complete the study.&#xD;
&#xD;
      PRIMARY OUTCOMES&#xD;
&#xD;
      - Change in (Pocket Probing Depth) PPD: change in mean value for each patient will be&#xD;
      calculated. Baseline values will be compared to the values recorded at follow-up visits.&#xD;
&#xD;
      SECONDARY OUTCOMES&#xD;
&#xD;
        -  Pocket closure&#xD;
&#xD;
        -  Risk of progression of periodontitis&#xD;
&#xD;
        -  Change in BoP: change in percentage of sites positive to bleeding on probing.&#xD;
&#xD;
        -  Change in Plaque Index (PI): change in percentage of sites with presence of plaque.&#xD;
           Baseline values will be compared to the values recorded at follow-up visits.&#xD;
&#xD;
        -  Change in Periodontal Attachment Level (PAL): change in mean value for each patient will&#xD;
           be calculated. Baseline values will be compared to the values recorded at follow-up&#xD;
           visits.&#xD;
&#xD;
        -  Change in Recession (REC): change in mean value for each patient will be calculated.&#xD;
           Baseline values will be compared to the values recorded at follow-up visits.&#xD;
&#xD;
        -  Changes in microbial composition and proportion of sequences identified as Lactobacillus&#xD;
           reuteri in the deepest residual pockets&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Monocentric, Parallel-Arm, Patient, Statistician, Operator and Examiner are blinded, RCT</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PD (periodontal depth)</measure>
    <time_frame>baseline, 3 and 6 months</time_frame>
    <description>Change in mean PD value for each patient measured (from the gingival margin to the bottom of the pocket). Baseline values will be compared to the values recorded in the follow-up visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk progression of the periodontitis and the need of periodontal surgery</measure>
    <time_frame>6 months</time_frame>
    <description>Change in percentage of patient who need periodontal surgery. Periodontal stability is defined as &lt; 10% of sites bleeding on probing, no probing depths of 4 mm or greater that bleed on probing, and lack of progressive periodontal destruction. Baseline values will be compared to the values recorded in the follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pocket closure</measure>
    <time_frame>baseline, 3 and 6 months</time_frame>
    <description>Change in percentage of site &gt; 4mm. Baseline values will be compared to the values recorded in the follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological changes</measure>
    <time_frame>baseline, 3 and 6 months</time_frame>
    <description>changes in microbial composition (kind of bacteria) and proportion (% of pathogen) of sequences identified as Lactobacillus reuteri in the deepest residual pockets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in REC (Clinical Gingival Recession)</measure>
    <time_frame>baseline, 3 and 6 months</time_frame>
    <description>Change in mean of REC value for each patient should be calculated. Baseline values will be compared to the values recorded in the follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in CAL (Clinical Attachment Level)</measure>
    <time_frame>baseline, 3 and 6 months</time_frame>
    <description>Change in mean of CAL value for each patient should be calculated. Baseline values will be compared to the values recorded in the follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BOP (Bleeding on Probing)</measure>
    <time_frame>baseline, 3 and 6 months</time_frame>
    <description>Change in percentage of sites positive to bleeding on probing. Baseline values will be compared to the values recorded in the follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PI (Plaque Index)</measure>
    <time_frame>baseline, 3 and 6 months</time_frame>
    <description>Change in percentage of site with plaque. Baseline values will be compared to the values recorded in the follow-up visits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Periodontal Diseases</condition>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Collection of microbiological samples from the two deepest sites in two different quadrants.&#xD;
All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).&#xD;
Study lozenges without live bacteria are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROBIOTIC (L. Reuteri)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Collection of microbiological samples from the two deepest sites in two different quadrants.&#xD;
All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).&#xD;
Study lozenges containing Lactobacillus Reuteri are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic: Lactobacillus Reuteri</intervention_name>
    <description>Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2 × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB)</description>
    <arm_group_label>PROBIOTIC (L. Reuteri)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo lozenge. Will be identical in taste, texture and appearance to the Probiotic one.</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent Form.&#xD;
&#xD;
          -  Male and female subjects, aged 18-75 years, inclusive.&#xD;
&#xD;
          -  Good general health (free of systemic diseases such as diabetes, HIV infection or&#xD;
             genetic disorder, ongoing malignant disease of any type that could influence the&#xD;
             outcome of the treatment and might interfere with the evaluation of the study&#xD;
             objectives).&#xD;
&#xD;
          -  History of periodontitis staging III or IV grading B or C&#xD;
&#xD;
          -  At least 2 sites with probing depth ≥6 mm or pockets of 5 mm with bleeding on probing&#xD;
             in two different quadrants.&#xD;
&#xD;
          -  Previous periodontal non-surgical treatment at least 3 months maximum 6 months.&#xD;
&#xD;
          -  Availability for the 6-month duration of the study for an assigned subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not willing to follow the agreed protocol.&#xD;
&#xD;
          -  Presence of orthodontic appliances.&#xD;
&#xD;
          -  Smokers (more than 10 cigarettes per day)&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease and asthma.&#xD;
&#xD;
          -  Tumors or significant pathology of the soft or hard tissues of the oral cavity.&#xD;
&#xD;
          -  Current radiotherapy or chemotherapy.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Current or past (within 3 months prior to enrolment) administration of medications&#xD;
             that may influence periodontal conditions and/or interfere with healing following&#xD;
             periodontal treatment (i.e., corticosteroids, calcium channel blockers, systemic&#xD;
             antibiotics, ...).&#xD;
&#xD;
          -  History of allergy to Erythritol or chlorexidine.&#xD;
&#xD;
          -  Restorations on the teeth to be treated which may interfere with treatment&#xD;
             administration and/or scoring procedures, at the discretion of the examiner.&#xD;
&#xD;
          -  Use of systemically administered antibacterial agents or probiotics 3 months prior to&#xD;
             enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magda Mensi</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASST Spedali Civili di Brescia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magda Mensi</last_name>
    <phone>+390303995784</phone>
    <email>magda.mensi@unibs.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eleonora Scotti</last_name>
    <phone>+390303995784</phone>
    <email>eleonorascotti@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Magda Mensi</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magda Mensi</last_name>
      <phone>+390303995784</phone>
      <email>magda.mensi@unibs.it</email>
    </contact>
    <contact_backup>
      <last_name>Eleonora Scotti</last_name>
      <phone>+390303995784</phone>
      <email>eleonorascotti@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</investigator_affiliation>
    <investigator_full_name>Magda Mensi</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Lactobacillus reuteri</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Periodontal diseases</keyword>
  <keyword>GBT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT04478643/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04478643
org study id: PERIOPRO np.: 3965
nct id: NCT04478643
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
Literature shows the potential effectiveness of L. reuteri as an adjunct to non-surgical
      periodontal therapy in initial treatment of periodontitis, but also underlines the limits of
      the conclusions, and the heterogeneity and limited sample size of the available studies.
      Therefore, there is a need for longer-term, randomized, controlled studies. Moreover, only
      one study addresses the use of this probiotic during the supportive therapy, in particular in
      patients with severe forms of periodontitis, and only few patients were included.

      Patients meeting the criteria of periodontitis stage III and IV, grade C are considered to be
      affected by severe and advanced forms of periodontitis with a rapid rate of progression. This
      group of patients could particularly benefit from supplements for the maintenance of
      periodontal health.

      The hypothesis of the present randomized controlled trial is that the adjunctive use of
      probiotic treatment can bring clinical and microbiological advantages during the supportive
      therapy of periodontal disease, and reduce the number of residual pockets.

      To test this hypothesis, the patients, upon initial evaluation, will be divided in 2 study
      groups and, after a session of professional oral hygiene, will be prescribed one of the
      therapies below:

        -  PLACEBO: The patients of the control group will receive control lozenges without live
           bacteria;

        -  TEST: The patients of the probiotic group will receive probiotic lozenges containing
           Lactobacillus reuteri DSM 17938 and Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2
           × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB).

      The probiotic and control lozenges will be identical in taste, texture and appearance. The
      lozenges will be given to all patients to consume at home. The patients will be instructed to
      dissolve them on their tongue twice a day, preferably after brushing, for 3 weeks.

      Periodontal and microbiological parameters will be evaluated at 3 and 6 months after the
      initial therapy, and compared between the two groups.
Probiotics are defined as 'live microorganisms which, when administered in adequate amounts,
      confer a health benefit on the host'. The influence of probiotics on pathogens flora can
      derive from three principal modes of action: innate and acquired host defense modulation,
      production of antibacterial substances and competitive exclusion mechanism. In particular,
      Lactobacillus reuteri has been studied for its antibacterial and anti-inflammatory
      properties.

      It is a heterofermentative bacterium and the distinct strains have different characteristics.
      In particular it acts as an antibiotic, induces oxidative stress on pathogens, is resistant
      to proteolytic and lipolytic and present anti-inflammatory properties.

      TRIAL DESIGN Parallel-arm, mono-center, statistician operator and examiner blinded RCT. The
      trial will have 6 months of duration.

      STUDY POPULATION Forty-four (44) adults, aged 18-75 years, meeting the criteria of
      periodontitis stage III and IV, grade C, will be entered into study. It is expected that
      forty (40) subjects will complete the study.

      PRIMARY OUTCOMES

      - Change in (Pocket Probing Depth) PPD: change in mean value for each patient will be
      calculated. Baseline values will be compared to the values recorded at follow-up visits.

      SECONDARY OUTCOMES

        -  Pocket closure

        -  Risk of progression of periodontitis

        -  Change in BoP: change in percentage of sites positive to bleeding on probing.

        -  Change in Plaque Index (PI): change in percentage of sites with presence of plaque.
           Baseline values will be compared to the values recorded at follow-up visits.

        -  Change in Periodontal Attachment Level (PAL): change in mean value for each patient will
           be calculated. Baseline values will be compared to the values recorded at follow-up
           visits.

        -  Change in Recession (REC): change in mean value for each patient will be calculated.
           Baseline values will be compared to the values recorded at follow-up visits.

        -  Changes in microbial composition and proportion of sequences identified as Lactobacillus
           reuteri in the deepest residual pockets
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Monocentric, Parallel-Arm, Patient, Statistician, Operator and Examiner are blinded, RCT
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Change in PD (periodontal depth)
time frame: baseline, 3 and 6 months
description: Change in mean PD value for each patient measured (from the gingival margin to the bottom of the pocket). Baseline values will be compared to the values recorded in the follow-up visits.
measure: Risk progression of the periodontitis and the need of periodontal surgery
time frame: 6 months
description: Change in percentage of patient who need periodontal surgery. Periodontal stability is defined as < 10% of sites bleeding on probing, no probing depths of 4 mm or greater that bleed on probing, and lack of progressive periodontal destruction. Baseline values will be compared to the values recorded in the follow-up visits.
measure: Pocket closure
time frame: baseline, 3 and 6 months
description: Change in percentage of site > 4mm. Baseline values will be compared to the values recorded in the follow-up visits.
measure: Microbiological changes
time frame: baseline, 3 and 6 months
description: changes in microbial composition (kind of bacteria) and proportion (% of pathogen) of sequences identified as Lactobacillus reuteri in the deepest residual pockets
measure: change in REC (Clinical Gingival Recession)
time frame: baseline, 3 and 6 months
description: Change in mean of REC value for each patient should be calculated. Baseline values will be compared to the values recorded in the follow-up visits.
measure: change in CAL (Clinical Attachment Level)
time frame: baseline, 3 and 6 months
description: Change in mean of CAL value for each patient should be calculated. Baseline values will be compared to the values recorded in the follow-up visits.
measure: Change in BOP (Bleeding on Probing)
time frame: baseline, 3 and 6 months
description: Change in percentage of sites positive to bleeding on probing. Baseline values will be compared to the values recorded in the follow-up visits.
measure: Change in PI (Plaque Index)
time frame: baseline, 3 and 6 months
description: Change in percentage of site with plaque. Baseline values will be compared to the values recorded in the follow-up visits.
arm group label: PLACEBO
arm group type: Placebo Comparator
description: Collection of microbiological samples from the two deepest sites in two different quadrants.
All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).
Study lozenges without live bacteria are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks.
arm group label: PROBIOTIC (L. Reuteri)
arm group type: Experimental
description: Collection of microbiological samples from the two deepest sites in two different quadrants.
All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).
Study lozenges containing Lactobacillus Reuteri are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks.
intervention type: Dietary Supplement
intervention name: Probiotic: Lactobacillus Reuteri
description: Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2 × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB)
arm group label: PROBIOTIC (L. Reuteri)
intervention type: Dietary Supplement
intervention name: Placebo
description: Placebo lozenge. Will be identical in taste, texture and appearance to the Probiotic one.
arm group label: PLACEBO
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Magda Mensi
role: Principal Investigator
affiliation: ASST Spedali Civili di Brescia
last name: Magda Mensi
phone: +390303995784
email: magda.mensi@unibs.it
last name: Eleonora Scotti
phone: +390303995784
email: eleonorascotti@hotmail.com
facility: 
status: Recruiting
contact: 
contact backup: 
country: Italy
responsible party type: Principal Investigator
investigator affiliation: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
investigator full name: Magda Mensi
investigator title: Principal investigator
mesh term: Periodontitis
mesh term: Periodontal Diseases
sharing ipd: No
provided document: 